The company manufactures and distributes surgical equipment and medical adhesive products, such as surgical tapes and dressings, for the healthcare industry in India and international markets.
The company lacks a durable moat, as evidenced by low average net margins of 2.1% and a ROCE of 6.4%, which is likely below its cost of capital. While it claims a technological edge, the business operates in a highly competitive medical disposables market where it acts primarily as a distributor or job-work processor without significant pricing power.
Capital allocation is poor, characterized by low returns on reinvested capital and a lack of clear strategy beyond maintaining operations. The company recently increased capital advances significantly for new machinery, but historical ROE of 3.8% suggests a track record of value destruction relative to inflation.
The investment collapsed as the company's chronic inability to generate returns above its cost of capital finally exhausted its cash reserves. The historical ROE of 3.8% proved to be a harbinger of total value destruction, as capital advances for new machinery failed to translate into earnings growth. The lack of internal controls over inventory and financial reporting, previously flagged by auditors, eventually masked a liquidity crisis that was exacerbated by slow receivable collections and excessive managerial pay, leaving the business unable to compete in a commoditized market.
RichFakir rates KMS Medisurgi Ltd's business quality as poor — 28/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, KMS Medisurgi Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on KMS Medisurgi Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of KMS Medisurgi Ltd's fair value is about ₹10 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →